Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 689

1.

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.

Caocci G, Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Sgherza N, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Gugliotta G, Baratè C, Scaffidi L, Elena C, Pirillo F, Scalzulli E, La Nasa G, Foà R, Breccia M.

Hematol Oncol. 2019 Mar 20. doi: 10.1002/hon.2606. [Epub ahead of print]

PMID:
30892724
2.

Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Cuneo A, Foà R.

Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019024. doi: 10.4084/MJHID.2019.024. eCollection 2019.

3.

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Molica M, Scalzulli E, Colafigli G, Foà R, Breccia M.

Ther Adv Hematol. 2019 Mar 1;10:2040620719826444. doi: 10.1177/2040620719826444. eCollection 2019. Review.

4.

Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol.

La Rocca U, Perrone MP, Piciocchi A, Cinti P, Barberi W, Gozzer M, Baftii MS, Torelli GF, Quattrocchi L, Gesuiti P, Lattanzi R, Cavallari C, Ricci R, Laurenti L, Foà R, Girelli G, Iori AP.

Bone Marrow Transplant. 2019 Mar 4. doi: 10.1038/s41409-019-0497-1. [Epub ahead of print] No abstract available.

PMID:
30833741
5.

Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Foà R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Rambaldi A, Ribera JM, Schoonen M, Stieglmaier JM, Zugmaier G, Bassan R.

Hematology. 2019 Dec;24(1):337-348. doi: 10.1080/16078454.2019.1567654.

PMID:
30757960
6.

Another step forward in the 20-year history of IGHV mutations in chronic lymphocytic leukemia.

Giudice ID, Foà R.

Haematologica. 2019 Feb;104(2):219-221. doi: 10.3324/haematol.2018.207399. No abstract available.

7.

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P.

Bone Marrow Transplant. 2019 Jan 21. doi: 10.1038/s41409-019-0448-x. [Epub ahead of print]

PMID:
30664723
8.

Intravenous arsenic trioxide and all-trans retinoic acid as front-line therapy for low-risk acute promyelocytic leukemia.

Breccia M, Foà R.

Expert Rev Hematol. 2019 Feb;12(2):81-87. doi: 10.1080/17474086.2019.1562332. Epub 2019 Jan 7.

PMID:
30572725
9.

BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?

Chiaretti S, Messina M, Foà R.

Cancer. 2019 Jan 15;125(2):194-204. doi: 10.1002/cncr.31848. Epub 2018 Dec 18. Review.

PMID:
30561755
10.

Chemotherapy-free and reduced intensity approaches in elderly patients with B-lineage acute lymphoblastic leukemia.

Chiaretti S, Foà R.

Eur J Intern Med. 2018 Dec;58:22-27. doi: 10.1016/j.ejim.2018.05.028. Review.

PMID:
30527919
11.

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.

Breccia M, Bartoletti D, Bonifacio M, Palumbo GA, Polverelli N, Abruzzese E, Bergamaschi M, Tieghi A, Tiribelli M, Iurlo A, Cavazzini F, Sgherza N, Binotto G, Isidori A, D'Adda M, Crugnola M, Bosi C, Heidel F, Molica M, Scaffidi L, Cattaneo D, Latagliata R, Auteri G, Lemoli RM, Fanin R, Russo D, Aversa F, Cuneo A, Semenzato G, Catani L, Cavo M, Vianelli N, Foà R, Palandri F.

Ann Hematol. 2019 Apr;98(4):889-896. doi: 10.1007/s00277-018-3569-1. Epub 2018 Dec 4.

PMID:
30515542
12.

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, Cornelissen JJ, Doubek M, Esteve J, Fielding A, Foa R, Gorin NC, Gökbuget N, Hallböök H, Hoelzer D, Paravichnikova E, Ribera JM, Savani B, Rijneveld AW, Schmid C, Wartiovaara-Kautto U, Mohty M, Nagler A, Dombret H.

Bone Marrow Transplant. 2018 Nov 1. doi: 10.1038/s41409-018-0373-4. [Epub ahead of print] Review.

13.

Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.

Guarini A, Peragine N, Messina M, Marinelli M, Ilari C, Cafforio L, Raponi S, Bonina S, Mariglia P, Mauro FR, Gaidano G, Del Giudice I, Foà R.

Br J Haematol. 2019 Feb;184(3):392-396. doi: 10.1111/bjh.15613. Epub 2018 Oct 18.

PMID:
30338509
14.

Real-Life Management of Children and Adolescents with Chronic Myeloid Leukemia: The Italian Experience.

Giona F, Santopietro M, Menna G, Putti MC, Micalizzi C, Santoro N, Ziino O, Mura R, Ladogana S, Iaria G, Sau A, Burnelli R, Vacca N, Bernasconi S, Consarino C, Petruzziello F, Moleti ML, Biondi A, Locatelli F, Foà R.

Acta Haematol. 2018;140(2):105-111. doi: 10.1159/000491546. Epub 2018 Sep 18.

PMID:
30227398
15.

Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

Fedullo AL, Messina M, Elia L, Piciocchi A, Gianfelici V, Lauretti A, Soddu S, Puzzolo MC, Minotti C, Ferrara F, Martino B, Chiusolo P, Calafiore V, Paolini S, Vignetti M, Vitale A, Guarini A, Foà R, Chiaretti S.

Haematologica. 2019 Feb;104(2):312-318. doi: 10.3324/haematol.2018.196055. Epub 2018 Sep 6.

16.

IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.

Gianfelici V, Messina M, Paoloni F, Peragine N, Lauretti A, Fedullo AL, Di Giacomo F, Vignetti M, Vitale A, Guarini A, Chiaretti S, Foà R.

Leuk Lymphoma. 2018 Sep 6:1-4. doi: 10.1080/10428194.2018.1499906. [Epub ahead of print] No abstract available.

PMID:
30188230
17.

Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.

Gentile M, Shanafelt TD, Mauro FR, Reda G, Rossi D, Laurenti L, Del Principe MI, Cutrona G, Angeletti I, Coscia M, Herishanu Y, Chiarenza A, Molica S, Ciolli S, Goldschmidt N, Angrilli F, Giordano A, Rago A, Bairey O, Tripepi G, Chaffee KG, Sameer PA, Vigna E, Zirlik K, Shvidel L, Innocenti I, Recchia AG, Di Raimondo F, Del Poeta G, Cortelezzi A, Neri A, Ferrarini M, Gaidano G, Kay NE, Polliack A, Foà R, Morabito F.

Eur J Haematol. 2018 Jul 24. doi: 10.1111/ejh.13149. [Epub ahead of print] No abstract available.

PMID:
30039576
18.

Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases.

Morabito F, Shanafelt TD, Gentile M, Reda G, Mauro FR, Rossi D, Di Renzo N, Molica S, Angrilli F, Chiarenza A, Cutrona G, Chaffee KG, Parikh SA, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Cortelezzi A, Gaidano G, Di Raimondo F, Fais F, Foà R, Neri A, Ferrarini M.

Am J Hematol. 2018 Sep;93(9):E216-E219. doi: 10.1002/ajh.25206. Epub 2018 Jul 30. No abstract available.

PMID:
29984867
19.

Cytomegalovirus Serostatus Affects Autoreactive NK Cells and Outcomes of IL2-Based Immunotherapy in Acute Myeloid Leukemia.

Bernson E, Hallner A, Sander FE, Nicklasson M, Nilsson MS, Christenson K, Aydin E, Liljeqvist JÅ, Brune M, Foà R, Aurelius J, Martner A, Hellstrand K, Thorén FB.

Cancer Immunol Res. 2018 Sep;6(9):1110-1119. doi: 10.1158/2326-6066.CIR-17-0711. Epub 2018 Jul 6.

PMID:
29980537
20.

Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.

Leblond V, Aktan M, Ferra Coll CM, Dartigeas C, Kisro J, Montillo M, Raposo J, Merot JL, Robson S, Gresko E, Bosch F, Stilgenbauer S, Foà R.

Haematologica. 2018 Nov;103(11):1889-1898. doi: 10.3324/haematol.2017.186387. Epub 2018 Jul 5.

21.

Current and future therapeutic approaches for the treatment of follicular lymphoma.

Pulsoni A, Cappelli LV, Ballotta L, Canichella M, Serrao A, Annechini G, D'Elia GM, Foà R.

Expert Rev Anticancer Ther. 2018 Sep;18(9):931-941. doi: 10.1080/14737140.2018.1493926. Epub 2018 Jul 16. Review.

PMID:
29972084
22.

Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia.

Mauro FR, Caputo MD, Rosati S, Pepe S, De Benedittis D, De Luca ML, Foà R.

Expert Rev Hematol. 2018 Aug;11(8):601-611. doi: 10.1080/17474086.2018.1495557. Epub 2018 Jul 18. Review.

PMID:
29969322
23.

Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.

Cicconi L, Breccia M, Franceschini L, Latagliata R, Molica M, Divona M, Diverio D, Rizzo M, Ottone T, Iaccarino L, Alfonso V, Foa R, Voso MT, Lo-Coco F.

Ann Hematol. 2018 Oct;97(10):1797-1802. doi: 10.1007/s00277-018-3400-z. Epub 2018 Jun 27.

PMID:
29951912
24.

Gaucher Disease and Myelofibrosis: A Combined Disease or a Misdiagnosis?

Mariani S, Palumbo G, Cardarelli L, Santopietro M, Foà R, Giona F.

Acta Haematol. 2018;139(4):240-242. doi: 10.1159/000489251. Epub 2018 Jun 26.

PMID:
29945135
25.

Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease.

Capria S, Pepe S, Trisolini SM, Testi AM, Vitale A, De Propris MS, Della Starza I, Elia L, Guarini A, Chiaretti S, Foà R.

Leuk Lymphoma. 2019 Jan;60(1):274-276. doi: 10.1080/10428194.2018.1468895. Epub 2018 Jun 26. No abstract available.

PMID:
29944039
26.

Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

Latagliata R, Breccia M, Carmosino I, Cesini L, De Benedittis D, Mohamed S, Vozella F, Molica M, Campanelli M, De Luca ML, Colafigli G, Quattrocchi L, Loglisci MG, Massaro F, Canichella M, Diverio D, Mancini M, Alimena G, Foà R.

Eur J Haematol. 2018 Jun 13. doi: 10.1111/ejh.13110. [Epub ahead of print]

PMID:
29896890
27.

Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.

Molica M, Scalzulli E, Colafigli G, Fegatelli DA, Massaro F, Latagliata R, Foà R, Breccia M.

Ann Hematol. 2018 Oct;97(10):1803-1808. doi: 10.1007/s00277-018-3375-9. Epub 2018 May 27.

PMID:
29806063
28.

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.

Testi AM, Pession A, Diverio D, Grimwade D, Gibson B, de Azevedo AC, Moran L, Leverger G, Elitzur S, Hasle H, van der Werff ten Bosch J, Smith O, De Rosa M, Piciocchi A, Lo Coco F, Foà R, Locatelli F, Kaspers GJL.

Blood. 2018 Jul 26;132(4):405-412. doi: 10.1182/blood-2018-03-836528. Epub 2018 May 22.

PMID:
29789356
29.

Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.

Raponi S, Del Giudice I, Ilari C, Cafforio L, Messina M, Cappelli LV, Bonina S, Piciocchi A, Marinelli M, Peragine N, Mariglia P, Mauro FR, Rigolin GM, Rossi F, Bomben R, Dal Bo M, Del Poeta G, Diop F, Favini C, Rossi D, Gaidano G, Cuneo A, Gattei V, Guarini A, Foá R.

Br J Haematol. 2018 May 22. doi: 10.1111/bjh.15405. [Epub ahead of print] No abstract available.

PMID:
29785734
30.

Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study.

Stilgenbauer S, Leblond V, Foà R, Böttcher S, Ilhan O, Knauf W, Mikuskova E, Renner C, Tausch E, Woszczyk D, Gresko E, Lundberg L, Moore T, Morris T, Robson S, Bosch F.

Leukemia. 2018 Aug;32(8):1778-1786. doi: 10.1038/s41375-018-0146-5. Epub 2018 Apr 27.

31.

Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications.

Chiaretti S, Messina M, Grammatico S, Piciocchi A, Fedullo AL, Di Giacomo F, Peragine N, Gianfelici V, Lauretti A, Bareja R, Martelli MP, Vignetti M, Apicella V, Vitale A, Li LS, Salek C, Elemento O, Inghirami G, Weinstock DM, Guarini A, Foà R.

Br J Haematol. 2018 Jun;181(5):642-652. doi: 10.1111/bjh.15251. Epub 2018 Apr 19.

PMID:
29675955
32.

Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.

Breccia M, Abruzzese E, Castagnetti F, Bonifacio M, Gangemi D, Sorà F, Iurlo A, Luciano L, Gozzini A, Gentile M, Bocchia M, Luzi D, Maggi A, Sgherza N, Isidori A, Crugnola M, Pregno P, Scortechini AR, Capodanno I, Pizzuti M, Foà R.

Ann Hematol. 2018 Sep;97(9):1577-1580. doi: 10.1007/s00277-018-3337-2. Epub 2018 Apr 19.

PMID:
29675611
33.

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Cuneo A, Follows G, Rigolin GM, Piciocchi A, Tedeschi A, Trentin L, Perez AM, Coscia M, Laurenti L, Musuraca G, Farina L, Delgado AR, Orlandi EM, Galieni P, Mauro FR, Visco C, Amendola A, Billio A, Marasca R, Chiarenza A, Meneghini V, Ilariucci F, Marchetti M, Molica S, Re F, Gaidano G, Gonzalez M, Forconi F, Ciolli S, Cortelezzi A, Montillo M, Smolej L, Schuh A, Eyre TA, Kennedy B, Bowles KM, Vignetti M, de la Serna J, Moreno C, Foà R, Ghia P; GIMEMA, European Research Initiative on CLL (ERIC) and UK CLL forum.

Haematologica. 2018 Jul;103(7):1209-1217. doi: 10.3324/haematol.2018.189837. Epub 2018 Apr 19.

34.

Gene mutations in lenalidomide-treated CLL.

Mauro FR, Foà R.

Blood. 2018 Apr 19;131(16):1769-1771. doi: 10.1182/blood-2018-02-830406. No abstract available.

PMID:
29674351
35.

Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis.

Caocci G, Mulas O, Annunziata M, Luciano L, Bonifacio M, Orlandi EM, Pregno P, Galimberti S, Russo Rossi A, Abruzzese E, Iurlo A, Martino B, Sgherza N, Binotto G, Castagnetti F, Gozzini A, Fozza C, Bocchia M, Sicuranza A, Stagno F, Efficace F, Usala E, De Gregorio F, Scaffidi L, Elena C, Pirillo F, Baratè C, Trawinska MM, Cattaneo D, Labate C, Gugliotta G, Molica M, Specchia G, La Nasa G, Foà R, Breccia M.

Am J Hematol. 2018 Jul;93(7):E159-E161. doi: 10.1002/ajh.25102. Epub 2018 Apr 28. No abstract available.

PMID:
29633312
36.

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms.

Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Brusa D, Deaglio S, Chiaretti S, Bruna R, Gottardi D, Massaia M, Giacomo FD, Guarini AR, Foà R, Kyriakides PW, Bareja R, Elemento O, Chichili GR, Monteleone E, Moore PA, Johnson S, Bonvini E, Cignetti A, Inghirami G.

Oncoimmunology. 2018 Feb 8;7(4):e1341032. doi: 10.1080/2162402X.2017.1341032. eCollection 2018.

37.

In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics.

Rigolin GM, Saccenti E, Guardalben E, Cavallari M, Formigaro L, Zagatti B, Visentin A, Mauro FR, Lista E, Bassi C, Lupini L, Quaglia FM, Urso A, Bardi MA, Bonaldi L, Volta E, Tammiso E, Ilari C, Cafforio L, Melandri A, Cavazzini F, Negrini M, Semenzato G, Trentin L, Foà R, Cuneo A.

Br J Haematol. 2018 Apr;181(2):229-233. doi: 10.1111/bjh.15174. Epub 2018 Apr 2.

PMID:
29611195
38.

Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.

Gentile M, Shanafelt TD, Reda G, Mauro FR, Zirlik K, Ciolli S, Laurenti L, Del Principe MI, Rossi D, Di Renzo N, Molica S, Angrilli F, Coscia M, Chiarenza A, Giordano A, Cutrona G, Chaffee KG, Parikh SA, Uccello G, Innocenti I, Tripepi G, D'Arrigo G, Vigna E, Recchia AG, Herishanu Y, Shvidel L, Tadmor T, Cortelezzi A, Del Poeta G, Gaidano G, Di Raimondo F, Neri A, Ferrarini M, Foà R, Polliack A, Morabito F.

Leukemia. 2018 Aug;32(8):1869-1873. doi: 10.1038/s41375-018-0100-6. Epub 2018 Mar 20. No abstract available.

PMID:
29588545
39.

Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.

Boriani G, Corradini P, Cuneo A, Falanga A, Foà R, Gaidano G, Ghia PP, Martelli M, Marasca R, Massaia M, Mauro FR, Minotti G, Molica S, Montillo M, Pinto A, Tedeschi A, Vitolo U, Zinzani PL.

Hematol Oncol. 2018 Oct;36(4):624-632. doi: 10.1002/hon.2503. Epub 2018 Mar 7. Review.

PMID:
29512173
40.

Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.

Breccia M, Foà R.

Curr Oncol Rep. 2018 Mar 6;20(3):23. doi: 10.1007/s11912-018-0669-y. Review.

PMID:
29511948
41.

Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.

Mariani S, Trisolini SM, Capria S, Moleti ML, Chisini M, Ferrazza G, Bafti MS, Limongiello MA, Miulli E, Peyvandi F, Foà R, Testi AM.

Haematologica. 2018 Mar;103(3):e138-e140. doi: 10.3324/haematol.2017.185363. No abstract available.

42.

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib.

Breccia M, Molica M, Colafigli G, Massaro F, Quattrocchi L, Latagliata R, Mancini M, Diverio D, Guarini A, Alimena G, Foà R.

Oncotarget. 2017 Dec 26;9(7):7534-7540. doi: 10.18632/oncotarget.23691. eCollection 2018 Jan 26.

43.

High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.

La Starza R, Messina M, Gianfelici V, Pierini V, Matteucci C, Pierini T, Limongi MZ, Vitale A, Roti G, Chiaretti S, Foà R, Mecucci C.

Leukemia. 2018 Aug;32(8):1807-1810. doi: 10.1038/s41375-018-0031-2. Epub 2018 Feb 2. No abstract available.

PMID:
29479063
44.

Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders.

De Luca G, Trasarti S, Bizzoni L, Del Giudice I, Della Starza I, De Propris MS, Gentile G, Mancini F, Mantovani S, Petrucci L, Tabanelli V, Guarini A, Vignetti M, Foà R.

Leuk Lymphoma. 2018 Nov;59(11):2715-2718. doi: 10.1080/10428194.2018.1439583. Epub 2018 Feb 23. No abstract available.

PMID:
29473430
45.

Genetic landscape of ultra-stable chronic lymphocytic leukemia patients.

Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R.

Ann Oncol. 2018 Apr 1;29(4):966-972. doi: 10.1093/annonc/mdy021.

PMID:
29365086
46.

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.

van Gorkom G, van Gelder M, Eikema DJ, Blok HJ, van Lint MT, Koc Y, Ciceri F, Beelen D, Chevallier P, Selleslag D, Blaise D, Foá R, Corradini P, Castagna L, Moreno C, Solano C, Müller LP, Tischer J, Hilgendorf I, Hallek M, Bittenbring J, Theobald M, Schetelig J, Kröger N; CLL subcommittee; Chronic Malignancies Working Party of the EBMT.

Bone Marrow Transplant. 2018 Mar;53(3):255-263. doi: 10.1038/s41409-017-0023-2. Epub 2017 Dec 18.

PMID:
29255169
47.

Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib.

Mauro FR, Foà R.

Lancet Oncol. 2018 Jan;19(1):7-8. doi: 10.1016/S1470-2045(17)30910-5. Epub 2017 Dec 12. No abstract available.

PMID:
29246804
48.

Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.

Gentile M, Shanafelt TD, Mauro FR, Laurenti L, Rossi D, Molica S, Vincelli I, Cutrona G, Uccello G, Pepe S, Vigna E, Tripepi G, Chaffee KG, Parikh SA, Bossio S, Recchia AG, Innocenti I, Pasquale R, Neri A, Ferrarini M, Gaidano G, Foà R, Morabito F.

Am J Hematol. 2018 Feb;93(2):E35-E37. doi: 10.1002/ajh.24960. Epub 2017 Nov 23. No abstract available.

49.

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience.

Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG.

Adv Ther. 2017 Oct;34(10):2232-2273. doi: 10.1007/s12325-017-0612-x. Epub 2017 Oct 5. Review.

50.

Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.

Breccia M, Colafigli G, Molica M, Scalzulli E, Diverio D, Latagliata R, Guarini A, Foà R.

Am J Hematol. 2017 Dec;92(12):E668-E670. doi: 10.1002/ajh.24916. Epub 2017 Oct 19. No abstract available.

Supplemental Content

Support Center